EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of Reporting Trends of Serious Adverse Events Associated With Anti‐Obesity Drugs

Branislava B Raičević, Andrej Belančić iD, Nikola Mirković, Slobodan M Janković

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Branislava B Raičević und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Concern over the side effects of anti‐obesity medications, particularly if severe, has grown as their use has increased. Thus, the objective was to use trends in the reporting of suspected adverse events associated with anti‐obesity medications that have been approved for sale in the European Union to attempt to uncover discrepancies in the safety of these medications. The study was designed as secondary research, based on data about the number of adverse drug reactions (both serious and non‐serious) reported to the EudraVigilance database. Trends of the annual reporting rates for the six anti‐obesity drugs were analyzed by the Joinpoint Trend Analysis Software that divides the trendline into an optimum number of segments connected by “joinpoints” and tests the significance of the trend within each segment. The trends of serious adverse drug events showed clear differences among the anti‐obesity drugs: while all drugs had significant increasing trends during a few initial years after their appearance on the market, only the annual number of reports for semaglutide continued to grow ever since (annual change + 67.1%, p = 0.000). On the contrary, a continuous increase in the reporting rate of non‐serious adverse drug events was observed only for liraglutide (annual change + 33.8%, p = 0.000) while for the other anti‐obesity drugs, including semaglutide, the trends after the initial period were either negative or did not increase significantly. In conclusion, among the anti‐obesity drugs currently approved, only semaglutide shows a continuously increasing trend in the annual reporting of serious adverse events, suggesting a need for further investigation of safety signals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Obesity AgentsAdverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsHumansDatabases, FactualEuropean UnionPharmacovigilanceLiraglutideObesityGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

anti‐obesity drugssemaglutideserious adverse drug eventstrends analysis

Substanzen

Anti-Obesity AgentsLiraglutideGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • University of Kragujevac, Faculty of Medical Sciences, Kragujevac, Serbia.
  • Department of Basic and Clinical Pharmacology and Toxicology, University of Rijeka, Faculty of Medicine, Rijeka, Croatia.

ORCID-Profile: Andrej Belančić

Zitieren

APA

Raičević, B. B., Belančić, A., Mirković, N., & Janković, S. M. (2025). Analysis of Reporting Trends of Serious Adverse Events Associated With Anti‐Obesity Drugs. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70080

Vancouver

Raičević BB, Belančić A, Mirković N, Janković SM. Analysis of Reporting Trends of Serious Adverse Events Associated With Anti‐Obesity Drugs. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70080

BibTeX
@article{Raievi2025,
  author = {Raičević, Branislava B and Belančić, Andrej and Mirković, Nikola and Janković, Slobodan M},
  title = {Analysis of Reporting Trends of Serious Adverse Events Associated With Anti‐Obesity Drugs},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70080}
}
Kostenlos starten →